Carpenter Rick 4

What Happened

• Rick Carpenter, EVP & Chief Technology Officer of Tandem Diabetes Care (TNDM), received a grant of 26,003 restricted stock units (RSUs) on 2026-05-29. The Form 4 records the acquisition price as $0.00 (award/derivative), so no cash was paid at grant.

Key Details

• Transaction date: 2026-05-29; Transaction type: Award/Grant (code A); recorded price: $0.00.
• Shares acquired: 26,003 RSUs (derivative award — contingent right to stock or cash).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Vesting (per footnotes): 1/3 vests on 5/29/2027; the remaining RSUs vest in eight equal quarterly installments on the 15th of the month thereafter.
• Filing: Reported on 2026-06-02 — filed within the required Form 4 window (timely). Remark: Ex. 24 Power of Attorney included in filing.
• Notes: The award is recorded as a derivative grant (RSUs); not an open-market purchase or sale.

Context

• RSUs are compensation awards that represent a contingent right to receive common stock (or cash in lieu) under the company’s 2023 Long-Term Incentive Plan. They do not provide immediately tradable shares until they vest and are settled.
• Such grants are routine for executive compensation and primarily serve retention/incentive purposes; they are not the same signal as an insider purchasing shares on the open market.